82 results
Page 2 of 5
6-K
EX-99
3kaftxhqkw6bld
28 Sep 23
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination
7:11am
6-K
EX-99
ucbt zp3ju
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
904k50xgq4 bm9q1
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
2dr9ltq1nei 79unr
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
kod5b numpkhz03g
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
omt 4zy1za0koj0
20 Dec 22
BioLineRx Announces Results from Phase 1/2a Study of Investigational
7:08am
6-K
EX-99
8er3lsy0a
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
l45ryqop
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
o4bxi7a
10 Nov 22
Current report (foreign)
7:08am
6-K
EX-99
wimoqtr
4 Nov 22
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
4:35pm
6-K
EX-99
5ekw7szq 7ji18
3 Nov 22
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma
9:20am
6-K
EX-99
vme92abqtj56 uid
27 Sep 22
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
7:00am
424B5
c80gjkd76zgana948b
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
b2ryqng
19 Sep 22
BioLineRx Announces $15 Million Registered Direct Offering
8:08am
6-K
EX-99
34dv1lhdv2dmbh ir
15 Sep 22
Current report (foreign)
8:39am
6-K
EX-99
uf9 lt8y1vc
12 Sep 22
BioLineRx Announces Submission of New Drug Application
8:16am
6-K
EX-99
8709b iple72jsu3
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
1s2cymqu156mn83pg5
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
c7f s72t0xf
28 Jun 22
BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in
7:14am
6-K
EX-99
40c0mvs9xlg
16 Jun 22
BioLineRx Announces Appointment of Commercial Strategy
7:05am